Comparative Pharmacology
Head-to-head clinical analysis: JUNIOR STRENGTH IBUPROFEN versus SOLARAZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNIOR STRENGTH IBUPROFEN versus SOLARAZE.
JUNIOR STRENGTH IBUPROFEN vs SOLARAZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis involved in pain, inflammation, and fever.
Solaraze (diclofenac sodium) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation and pain. In actinic keratosis, it may also induce apoptosis and decrease keratinocyte proliferation.
Oral: 200-400 mg every 4-6 hours as needed; maximum single dose 400 mg, maximum daily dose 1200 mg for OTC use.
Apply 0.5 mL (1 unit dose) topically to actinic keratoses twice daily for 2 to 4 weeks, then 1 week off, repeat for a total of 3 treatment cycles.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in children; prolonged in neonates or hepatic impairment.
Following topical application, the terminal elimination half-life of diclofenac from plasma is approximately 12 hours (range 8-15 hours). This reflects the slow absorption and distribution from the skin depot, with clinical relevance for twice-daily dosing.
Renal excretion of conjugated metabolites (approximately 70-90%) and unchanged drug (<10%). Biliary/fecal excretion accounts for <10%.
Solaraze (diclofenac sodium 3% gel) is primarily eliminated via hepatic metabolism followed by renal excretion of metabolites. Approximately 65% of a dose is excreted in urine as conjugated metabolites, with less than 1% as unchanged drug. About 35% is eliminated in feces via biliary excretion of metabolites.
Category D/X
Category C
NSAID
NSAID